Olive Polyphenols Reached the Colon in 62 Adults, But the Microbiome Barely Moved

If olive polyphenols act on the gut microbiome, two things have to be true: the compounds have to reach the colon, and the bacteria there have to do something with them. A 2019 randomized controlled trial in the European Journal of Nutrition tested both at once. Lorenza Conterno and colleagues fed 62 mildly hypercholesterolemic adults a biscuit enriched with olive pomace, the solid material left over after olives are pressed for oil, for eight weeks, then measured what came out in 24-hour urine and what showed up in the faecal microbiota. The metabolite result was emphatic. The microbiota result was not, and the gap between those two findings is the useful part of this paper.

Why This Study Matters

Most olive polyphenol research stops at the bloodstream. It measures how much hydroxytyrosol is absorbed, or what happens to a cardiovascular biomarker, and leaves the colon out of the story entirely. That is a real gap, because the compounds in olives do not travel as a single intact molecule. Oleuropein and its relatives are largely broken down in the stomach into hydroxytyrosol and tyrosol, and from there the path forks: some is absorbed in the small intestine and processed by the liver, and some continues into the colon, where resident bacteria keep working on it.

At the time this trial was published, no study had reported whether olives or olive pomace changed the relative abundances of human gut bacteria, and only a handful had tracked the small phenolic acids that come out of the combined host and microbial metabolism of olive polyphenols. Conterno and colleagues set out to measure both sides in the same people, in the same eight weeks.

The second reason it matters is the format. Rather than test an oil or a capsule, the researchers took a waste stream from olive oil production, olive pomace, and built it into a food. Pomace is still rich in polyphenols and, unlike oil, rich in fibre. That makes this trial an interesting delivery experiment and, as it turns out, a complicated one to interpret.

How It Was Designed

The study was double-blind, randomized, controlled and parallel, registered on ClinicalTrials.gov as NCT02664428 before the intervention ran between November 2015 and June 2016 at a specialist cardiovascular clinic in Arco, Italy.

Three design details are worth pulling out. First, the control biscuit was matched carefully: same appearance, taste and texture, food-grade colourings to match, low-polyphenol olive oil in place of the pomace, and near-identical energy content (419 versus 434 kcal per 100 g). Second, allocation concealment was genuine. An external individual assigned products to participant codes by drawing from a bag, matched only for age and sex, and the treatment codes were kept offsite and not released until the statistical analysis was finished. Third, compliance was verified rather than assumed. Participants returned every full or empty daily package for weighing, filled in weekly online questionnaires and daily tick sheets, and two people were excluded for leaving more than 25 percent of the product unconsumed.

The dose is worth stating precisely. Each 90 g daily portion of the olive biscuit delivered roughly 370 mg of total biophenols, of which about 15 mg came from the tyrosol group: hydroxytyrosol, tyrosol and their conjugated forms. That is around three times the 5 mg daily threshold EFSA set for its olive polyphenol health claim. The control biscuit delivered less than 1 mg of total biophenols.

Of 73 people enrolled, 62 completed: 32 women and 30 men, aged 30 to 65, BMI 20 to 29.9, total cholesterol between 180 and 240 mg/dl, none of them smokers, none on statins or lipid-affecting supplements. Five of the eleven who left did so because they did not like the taste of the biscuit.

What They Found

The clearest signal in the trial came from metabolites, not bacteria. Compared with the control biscuit, the olive biscuit produced significantly higher concentrations of a whole family of small phenolic acids in 24-hour urine, and two of them rose in fasted blood as well.

Metabolite	Olive group, before to after	Control, before to after	p-value	What it is
DOPAC (urine)	1.39 to 22.09	1.68 to 0.94	< 0.001	Hydroxytyrosol breakdown product
Homovanillic acid (urine)	20.96 to 54.41	21.63 to 19.62	< 0.001	Hydroxytyrosol breakdown product
3-Hydroxyphenylacetic acid (urine)	34.82 to 65.11	28.76 to 29.58	0.001	Microbial phenolic catabolite
3-(3-Hydroxyphenyl)propanoic acid (urine)	20.65 to 34.02	16.12 to 13.83	0.009	Microbial phenolic catabolite
Hippuric acid (urine)	746.62 to 917.46	789.12 to 734.80	0.014	Shared end product of many polyphenols
Protocatechuic acid (urine)	0.55 to 0.75	0.54 to 0.50	0.001	Phenolic acid
Caffeic acid (urine)	0.45 to 0.64	0.47 to 0.44	0.003	Phenolic acid
DOPAC (plasma)	0.010 to 0.651	0.006 to 0.021	< 0.001	Same metabolite, in circulation
Homovanillic acid (plasma)	0.093 to 0.217	0.069 to 0.090	0.003	Same metabolite, in circulation

All values are concentrations in micromoles per liter, urine normalized to 24-hour volume. Green marks the olive group's rise. Every row is a statistically significant difference versus control after factorial ANOVA with correction for multiple comparisons.

Reading the Results

The metabolites are the finding. Urinary DOPAC went from 1.39 to 22.09, close to a sixteen-fold rise, while the control group's fell. Homovanillic acid more than doubled. Both are downstream products of hydroxytyrosol, and both also appeared in fasted blood, meaning they were not just passing through the gut but circulating. Alongside them, catabolites that come specifically from microbial processing, 3-hydroxyphenylacetic acid and 3-(3-hydroxyphenyl)propanoic acid, rose significantly too. This is direct human evidence that a portion of ingested olive phenols, plus their metabolites, reaches the colon and gets worked on there. It is worth pairing with what is already known about the other fork in the road: olive phenols are among the better-absorbed dietary polyphenols in the small intestine, and the food matrix they arrive in changes how much gets through. Colonic metabolism is the second act, not a consolation prize for poor absorption.

The bacteria barely moved. This is where the paper is admirably restrained. Overall microbiota diversity did not shift: alpha diversity p = 0.29, beta diversity p = 0.66. At genus level, 16S sequencing found significant but, in the authors' own words, very small differences, and they went the direction most people would not predict. Lactobacillus and Ruminococcus were lower in the olive group than in the control group. Bifidobacteria showed a consistent upward trend across all three measurement methods, 16S sequencing, fluorescence in situ hybridization and qPCR, but reached statistical significance in none of them. A trend that repeats across three independent methods is worth noting. It is not a result.

Men and women metabolized it differently. After the olive biscuit, male participants excreted significantly more of several phenolic acids than female participants, including 4-hydroxyphenylacetic acid at 153.66 versus 105.41. The researchers then checked whether the gut communities differed by sex and found significant differences in the relative abundance of Akkermansia, Bifidobacterium, Bacteroides, Prevotella, Rikenellaceae, Barnesiellaceae and Enterobacteriaceae between men and women. The link between the two observations is proposed, not demonstrated, but it is one of the more interesting loose threads in the olive polyphenol literature.

What Didn't Change

Almost every clinical outcome. After eight weeks, there was no significant change in total cholesterol, LDL, HDL, triglycerides, apolipoprotein A1 or B, glucose, insulin, C-reactive protein, blood pressure, weight, BMI or urinary F2-isoprostane. Oxidized LDL drifted down in the olive group, from 59.8 to 57.3 U/L against a small rise in the control group, but the difference was not significant either over time or against control (p = 0.634). The authors describe it as a trend and nothing more, and so should anyone citing it.

Faecal microbiota diversity did not change. Bifidobacteria did not increase significantly. The trial was powered for LDL cholesterol, not for the metabolite work that turned out to be its strongest result.

Limits and What's Still Unknown

Two limits matter more than the rest. The first is that this was not olive oil. It was olive pomace baked into a biscuit alongside chestnut, pea and buckwheat flours, and the pomace supplied more than 90 percent of the polyphenols in the final product. Findings here describe that food, not a tablespoon of extra virgin olive oil and not a capsule.

The second is the fibre. The olive biscuit contained 13.3 g of dietary fibre per 100 g against 3.4 g in the control, so a 90 g daily portion carried roughly 12 g of fibre versus 3 g. The two biscuits were matched for calories, not for macronutrients. Fibre is itself bifidogenic, which means that even if the bifidobacteria trend had reached significance, it could not have been cleanly attributed to the polyphenols. The metabolite results are not vulnerable to this, since the phenolic acids measured are specific breakdown products of olive phenols, but any microbiota interpretation is.

Beyond that: eight weeks is a short window for composition change, 62 completers is a modest sample for microbiome work where between-person variation is enormous, and the participants were healthy apart from mildly raised cholesterol. Whether any of this translates into a clinical outcome remains unanswered here.

Broader Context

This trial sits in a small group of studies asking what olive phenols do below the small intestine. A 2021 review in Nutrition Reviews assembled the wider picture of olive oil and the gut microbiome and reached a similar altitude: the human composition data are suggestive, the mechanistic detail is mostly animal and in vitro. An earlier trial that Conterno's team cite found a small bifidobacteria increase in an olive oil intervention, but the significant lift came from the arm where thyme phenolics were blended into the oil, not the olive-only arm, which is a distinction worth keeping straight.

Where the whole-diet evidence is stronger, it is also less specific. A Mediterranean-diet intervention in 612 older adults reshaped the gut microbiome and lowered inflammation markers, but olive oil was one component of many. Conterno's design has the opposite trade: a clean, blinded comparison of one enriched food against a matched control, with a result that turned out to be about metabolism rather than composition.

It also belongs with the food-enrichment trials. Baking olive phenols into a staple is a recurring strategy in this literature, and a separate randomized trial using hydroxytyrosol-enriched bread in adults with type 2 diabetes reported changes in HbA1c that this biscuit trial did not see in its own metabolic markers. Different populations, different doses, different endpoints. For the plain-language version of where all of this leaves the question, see whether olive oil is good for gut health.

Related Research

Continue exploring olive oil and polyphenol science:

• Olive Oil and the Gut Microbiome: What a 2021 Review Found
• Mediterranean Diet Lowered Inflammation Markers and Reshaped the Gut Microbiome in 612 Older Adults
• Hydroxytyrosol-Enriched Bread Improved HbA1c in T2D Adults
• Gut Microbiome Explains 6% of Triglyceride Variance in 893 Adults

Source: View the original study on PubMed

Olivea's Dosage

This trial delivered about 15 mg per day of hydroxytyrosol and its derivatives, inside a 90 g biscuit. Olivea concentrates the same compound family instead: each Olivea capsule delivers over 20 mg of hydroxytyrosol, and our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study: we did not fund it, design it, or conduct it, and it did not test an Olivea product.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.